Table 2 The number of drugs with higher incidence of ADRs in the Japanese population classified according to the mechanism of action
From: Analysis and enhancement of risk management for ethnic differences in antineoplastic drugs in Japan
| Â | Myelosuppression- | ILD | Hepatic impairment | Renal impairment |
|---|---|---|---|---|
Antibody (7 drugs) | 4 (57.1%) | 2 (28.6%) | 2 (28.6%) | 0 (00.0%) |
Cytotoxic (4 drugs) | 4 (100.0%) | 0 (00.0%) | 3 (75.0%) | 0 (00.0%) |
Hormone (5 drugs) | 0 (00.0%) | 0 (00.0%) | 1 (20.0%) | 0 (00.0%) |
IO (6 drugs) | 1 (16.7%) | 1 (16.7%) | 2 (33.3%) | 0 (00.0%) |
TKI (22 drugs) | 11 (50.0%) | 3 (13.6%) | 11 (50.0%) | 7 (31.8%) |
Total (44 drugs) | 20 (45.5%) | 6 (13.6%) | 18 (40.9%) | 7(15.9%) |